Pfizer Outsources Branded Drug Production to Focus on Experimental Coronavirus Vaccine
Pfizer (NYSE: PFE) is taking on significant risk in a race to provide the world with a coronavirus vaccine. Pfizer is outsourcing the production of its own branded medicines to contract manufacturers such as Catalent (NYSE: CTLT) to make room for the production of, BNT162, an experimental SARS-CoV-2 vaccine the big pharma is developing in partnership with BioNTech (NASDAQ: BNTX).
The steps Pfizer is taking to ramp up the production of an experimental vaccine candidate that hasn't produced any clinical trial data yet are an extremely unusual gamble. Having millions of doses of BNT162 ready to ship out the moment it's potentially approved, though, could make it all worthwhile.
Image source: Getty Images.
Source Fool.com
